Cullina J[au] - Search Results

Year	Number of Results
1987	1
2003	1
2004	1
2005	1
2008	1
2010	1
2016	1
2017	3
2018	1
2020	1
2021	1
2022	1

1

Current management of bronchiectasis: review and 3 case studies.

Silverman E, Ebright L, Kwiatkowski M, Cullina J. Silverman E, et al. Among authors: cullina j. Heart Lung. 2003 Jan-Feb;32(1):59-64. doi: 10.1067/mhl.2003.9. Heart Lung. 2003. PMID: 12571549 Review.

2

Exploring the Relationship between FEV₁ Loss and Recovery and Aminoglycoside Pharmacokinetics in Adult Patients with Cystic Fibrosis: Implications for Clinical Dosing Strategies.

Hoff BM, Scheetz MH, Jain M, Cullina JF, Rhodes NJ. Hoff BM, et al. Among authors: cullina jf. Pharmacotherapy. 2020 Jun;40(6):584-591. doi: 10.1002/phar.2399. Epub 2020 May 5. Pharmacotherapy. 2020. PMID: 32259317

3

The relationship between sweat chloride levels and mortality in cystic fibrosis varies by individual genotype.

Espel JC, Palac HL, Bharat A, Cullina J, Prickett M, Sala M, McColley SA, Jain M. Espel JC, et al. Among authors: cullina j. J Cyst Fibros. 2018 Jan;17(1):34-42. doi: 10.1016/j.jcf.2017.11.002. Epub 2017 Dec 6. J Cyst Fibros. 2018. PMID: 29221674 Free article.

4

Aminoglycoside resistance of Pseudomonas aeruginosa in cystic fibrosis results from convergent evolution in the mexZ gene.

Prickett MH, Hauser AR, McColley SA, Cullina J, Potter E, Powers C, Jain M. Prickett MH, et al. Among authors: cullina j. Thorax. 2017 Jan;72(1):40-47. doi: 10.1136/thoraxjnl-2015-208027. Epub 2016 Jun 20. Thorax. 2017. PMID: 27325751 Free PMC article.

5

Risk factors for aminoglycoside ototoxicity in adult cystic fibrosis patients.

O'Donnell EP, Scarsi KK, Scheetz MH, Postelnick MJ, Cullina J, Jain M. O'Donnell EP, et al. Among authors: cullina j. Int J Antimicrob Agents. 2010 Jul;36(1):94-5. doi: 10.1016/j.ijantimicag.2010.02.018. Epub 2010 Apr 10. Int J Antimicrob Agents. 2010. PMID: 20382508 No abstract available.

6

Antibiotic duration and changes in FEV₁ are not associated with time until next exacerbation in adult cystic fibrosis: a single center study.

Espel JC, Palac HL, Cullina JF, Clarke AP, McColley SA, Prickett MH, Jain M. Espel JC, et al. Among authors: cullina jf. BMC Pulm Med. 2017 Nov 29;17(1):160. doi: 10.1186/s12890-017-0503-6. BMC Pulm Med. 2017. PMID: 29187171 Free PMC article.

7

Cystic fibrosis patients have poor sleep quality despite normal sleep latency and efficiency.

Jankelowitz L, Reid KJ, Wolfe L, Cullina J, Zee PC, Jain M. Jankelowitz L, et al. Among authors: cullina j. Chest. 2005 May;127(5):1593-9. doi: 10.1378/chest.127.5.1593. Chest. 2005. PMID: 15888833

8

Type III secretion phenotypes of Pseudomonas aeruginosa strains change during infection of individuals with cystic fibrosis.

Jain M, Ramirez D, Seshadri R, Cullina JF, Powers CA, Schulert GS, Bar-Meir M, Sullivan CL, McColley SA, Hauser AR. Jain M, et al. Among authors: cullina jf. J Clin Microbiol. 2004 Nov;42(11):5229-37. doi: 10.1128/JCM.42.11.5229-5237.2004. J Clin Microbiol. 2004. PMID: 15528719 Free PMC article.

9

Evolution of Pseudomonas aeruginosa type III secretion in cystic fibrosis: a paradigm of chronic infection.

Jain M, Bar-Meir M, McColley S, Cullina J, Potter E, Powers C, Prickett M, Seshadri R, Jovanovic B, Petrocheilou A, King JD, Hauser AR. Jain M, et al. Among authors: cullina j. Transl Res. 2008 Dec;152(6):257-64. doi: 10.1016/j.trsl.2008.10.003. Epub 2008 Oct 31. Transl Res. 2008. PMID: 19059160 Free PMC article.

10

Does developmental content influence the effectiveness of anticipatory guidance?

Dworkin PH, Allen D, Geertsma A, Solkoske L, Cullina J. Dworkin PH, et al. Among authors: cullina j. Pediatrics. 1987 Aug;80(2):196-202. Pediatrics. 1987. PMID: 3302923 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results